Tag: drug-coated devices
CX paclitaxel roundtable: “The benefits might have been a bit overstated”
A panel of experts in peripheral arterial disease (PAD) discuss recent developments in the use of paclitaxel-coated devices during CX 2026. Watch the full...
Drug-coated technology in PAD, part one: Where are we now?
Leading voices in the treatment of lower extremity vascular disease gather in the CX Studio to discuss the state of drug-coated technology use in...
IVUS is “not a free walk” – it is about the patient...
In conversation with Vascular News about IVUS, Eric Secemsky (Beth Israel Deaconess Medical Center, Boston, USA, and a newly appointed editor of Vascular News...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...
